Aptamers 2014 encourages demonstration of R&D and laboratory supplies related to DNA/RNA oligonucleotide research and invites commercial sponsorship. You are invited to choose from a variety of highly-competitive sponsorship packages listed below. If your needs are not covered by the offered packages please contact us in the first instance and we shall do our best to develop a package to suit your requirements.
To increase interaction with delegates, refreshments will be held in the main exhibition area. Spaces for exhibitions are limited and will be allocated on a first-come-first-served basis. To get a location of choice, and to avail our special promotional offers we strongly recommend an early booking.
Exhibition package includes the following benefits:
For a Booking Form and further information about packages and other promotional opportunities email on:
Terms & Conditions of Booking.
Aptamer Solutions Ltd is a York based Biotechnology Company specialising in the custom selection of high-affinity and highly specific nucleic acid aptamers for use in the life sciences sector. Our proprietary automated high-throughput aptamer selection processes allow us to offer a flexible and competitive pricing structure for the development of RNA and DNA aptamers. In addition, we are about to launch a new complementary technology in the area of biomarker discovery.
Our proprietary aptamer based biomarker discovery platform and proprietary combinatorial libraries contain up to and over 1018 different molecules, this diversity and bespoke library design is fundamental to the success of the screening process. This technology enables us to greatly speed up the identification of novel biomarkers as well as diagnostics and/or therapeutic candidate molecules. This technology builds on one of the most powerful uses of aptamer technology, which is the ability for aptamers to be isolated against targets without any prior knowledge of the target.
Our aptamer-based proteomic technology identifies novel biomarkers within the cell surface (such as tumours, cell lines or stem cells) or in samples of biological fluids (such as, urine, plasma and saliva). The technology is versatile and can also be applied to viruses, bacteria, fungi or any other cell based materials or extracts. The discovery process is driven by identifying differences between sample population using enormous aptamer libraries. Samples are prepared based on broad classifications such as: disease vs normal; pre-metastatic vs. post metastatic cancers; pathogenic vs non-pathogenic fungi etc. The process is fast and efficient and identifies differences between ‘healthy’ and ‘diseased’ whilst simultaneously developing the affinity reagent. This cuts out many of the steps associated with traditional biomarker discovery processes.
Integrated DNA Technologies (IDT) is a leader in the manufacture and development of products for the research and diagnostic life science market. T he largest supplier of custom nucleic acids in the world, IDT serves academic research, biotechnology, and pharmaceutical development communities.
IDT products support a wide variety of applications, including next generation sequencing (NGS), DNA amplification, SNP detection, microarray analysis, expression profiling, gene quantification, and synthetic biology. Platform-independent NGS products and services are available in addition to DNA and RNA oligonucleotides, qPCR assays, siRNA duplexes, and custom gene synthesis. Individually-synthesized xGen™ Lockdown™ Probes enable improved target capture. IDT also manufactures custom adaptors, fusion primers, Molecular Identifier tags (MIDs), and other workflow oligonucleotides for NGS. A TruGrade™ processing service is also available to reduce oligonucleotide crosstalk during multiplex NGS.
Serving over 80,000 life sciences researchers, IDT is widely recognized as the industry leader in custom oligonucleotide manufacture due to its unique capabilities. IDT pioneered the use of high throughput quality control (QC) methods and is the only oligonucleotide manufacturer to offer purity guarantees and 100% QC. Every oligonucleotide is analyzed by mass spectrometry and purified oligonucleotides receive further analysis by CE and HPLC. The company maintains an engineering division dedicated to advancing synthesis, processing technology, and automation. An in-house machine shop provides rapid prototyping and custom part design/control. Additionally, IDT offers unrivalled customer support, receiving approximately 100,000 calls annually with an average wait time of only 8 seconds.
A dedicated GMP manufacturing facility for molecular diagnostics provides oligonucleotides for In Vitro Diagnostic Devices (IVDs) or Analyte Specific Reagents (ASRs) for Laboratory-Developed Tests (LDTs). This manufacturing process is customer-defined and controlled, and facilitates progression from research to commercialization.
OVERVIEW: Izon designs and manufactures precision instrumentation for multi-parameter measurement of nano- and micro- sized particles. Izon’s instruments use unique nanopore-based detection to enable the size, charge and concentration of 50nm – 20 micron sized particles to be measured on a particle-by-particle basis, providing detail not available with optical-based techniques. Izon originated in New Zealand and now sells its products in 34 countries. It has its European headquarters in Oxford, UK and its US headquarters are in Cambridge, MA.
APPLICATIONS: The underlying measurement technique known as Tunable Resistive Pulse Sensing (TRPS) has been applied to enable high resolution analysis of a wide range of particle types in fields including:
PRODUCTS: Two instruments based on TRPS technology are currently commercially available:
Biomedical Diagnostics Projects: High-resolution detection of particle size and charge, enables assays to be developed for high sensitivity detection of target analytes. Projects are underway to combine magnetic particle sensing systems with TRPS to provide high-sensitivity diagnostics for clinical use that are faster and lower cost than existing methods.
IBA GmbH – Your partner for custom-made Aptamers
IBA GmbH is a biotech company located in Goettingen, Germany. Since 1991 our nucleic acid division has focused on specialized nucleic acid custom services, which require particular care and highest quality. These include custom-made DNA and RNA oligonucleotides, chimers, modified and labeled nucleic acids (e.g. for real-time PCR) as well as dinucleotides and triphosphates.
Taking advantage of the new Click Chemistry we can offer new dye combination options and unsurpassed labeling densities. More than 200 fluorescent labels and more than 80 modifications are available to suit your needs.
With our expertise in high quality oligonucleotide synthesis we produce custom DNA and RNA Aptamers according to your individual specifications. You ask for it – we synthesize! Just let us know your DNA/RNA sequence and required modification.
In collaboration with RiNA GmbH, Berlin, we are now also providing an Aptamer Generation Service (AGS), which enables the generation of new DNA or RNA Aptamers.
More details can be found at www.oligo-specialist.com.
RiNA GmbH, a biotech company located in Berlin (Germany), is active in the field of cell-free protein biosynthesis and functional nucleic acids, especially in aptamer technology and its application. RiNA provides both commercial protein expression kits and diverse services for protein and nucleic acids syntheses.
RiNA’s Functional Nucleic Acids (FuNA) division provides different services in the aptamer field, in particular:
Additionally, RiNA is currently involved in several national and international funded projects.
Base Pair Biotechnologies offers its customers a total solution for developing novel DNA and RNA aptamer-based technologies. In addition to our numerous institutional customers, we support companies developing products in areas ranging from basic research detection, to clinical diagnostics and therapeutic lead development. We have proven success with protein, peptide, small molecule and cellular targets.
Our platform technology is a patented, multiplexed approach to aptamer discovery. This allows us to offer de novo aptamer discovery services at unprecedented speed and throughput. Our expertise in aptamer and related assay development allows us to support our customers in a wide range of novel applications.
Scientists at Base Pair Biotechnologies have been studying aptamers and developing them on a research basis since 2004. Besides custom aptamer development through commercial and research requests Base Pair Biotechnologies is also involved in multiple projects funded through research grants. Current and past federally funded research projects involving aptamers include NIH, EPA and NSF grants totaling over $2.5M.
Besides our custom work we have hundreds of aptamers with validated binding on hand with various degrees of prior validation in assays as well. Our Aptamers that Work™ catalog and catalog incubator contain DNA and RNA aptamers available for use.